Sales 2025 by Business Segment

Sales 2025 by Geography

Historical Breakdown of Revenue by Business Segments

Net Income: Breakdown by Business Segment

Breakdown by Business Segment (DKK)
Fiscal Period: December 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

Pharmaceutical Products

          

Research, Development, Production and Sale of Pharmaceuticals

16.3B 18.25B 19.91B 22B 24.63B

Total Assets

34.65B 37.45B 37.41B 56.98B 52.05B

Interest Expense

-153M -103M -54M -113M -514M

Income Tax Expense

263M 558M 703M 576M 1.3B

CAPEX

-612M -820M -277M -508M -554M

EBT

1.58B 2.47B 2.99B 3.72B 4.49B

Gross Profit

12.65B 14.3B 15.43B 17.77B 20.36B

D&A

1.71B 1.81B 2.01B 1.88B 1.86B

Operating Income

2.01B 2.85B 3.2B 3.27B 5.28B

Net Income

1.32B 1.92B 2.29B 3.14B 3.19B

Geographical Revenue Distribution History

Geographical breakdown of sales (DKK)
Fiscal Period: December 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

United States

7.46B 9.1B 9.83B 11.32B 13.29B

Total Assets

12.78B 13.11B 12.03B 32.89B 29.15B

Europe

- 4.25B 4.63B 5.15B 5.82B

International Operations

4.16B 5.2B 4.99B 5.22B 4.86B

Total Assets

1.81B 1.55B 1.53B 1.52B 1.05B

Unallocated

400M -311M 464M 314M 666M

Unallocated Effects from Hedging

- - - - -

North America (Excl. US)

789M - - - -

Unallocated Other Revenue

- - - - -

Europe (Excl.Denmark)

3.47B - - - -

Denmark

30M - - - -

Total Assets

11.07B 10.78B 10.02B 8.93B 8.52B